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DOI 10.1016/j.stem.2009.10.009Previous studies have performed internal
matching of HLA and ABO blood type
data from either cadaveric organ donors
(Taylor et al., 2005) or a cord blood bank
(Nakajima et al., 2007) to estimate that
a theoretical collection of approximately
150–170 human embryonic stem cell
(hESC) lines with various HLA genotypes
or a collection of ten lines homozygous
for the common HLA types will suffice to
provide HLA-matches for populations in
the UK (Taylor et al., 2005) and Japan (Na-
kajima et al., 2007). In this report, we have
established a hESC bank containing 188
hESC lines mainly derived from abnormal
and poor-quality in vitro fertilization (IVF)-
derived embryos and have evaluated the
actual HLA-matching capacity of the
bank with respect to the regional popula-
tion. We find that the current bank could
provide a beneficial match for 24.9%–
56.3% of the local population, regardless
of ethnic differences.
Although hESCs are less susceptible to
immune reaction (Drukker et al., 2006),
these cells and their derivatives can
express human leukocyte antigen (HLA),
and the consequent major histocompati-
bility complex (MHC) incompatibility can
cause allograft rejection after transplanta-
tion (Bradley et al., 2002; Drukker and
Benvenisty, 2004). The previously theo-
retical calculations did not clarify in actual
situation (1) whether the embryos from
in vitro fertilization (IVF) treatment can
provide adequate HLA diversity for
matching; (2) whether the presumptive
populations used for modeling calcula-
tions in the Taylor et al. and Nakajima
et al. studies accurately reflect existing
populations; and (3) whether diversity
in the ethnic composition present in
different geographical regions influencesthe number of hESC lines required for
HLA matching. Moreover, the destruction
of large numbers of normal human
embryos to obtain cell lines is an ethically
controversial issue; thus, we undertook
this study to assess whether lines isolated
from embryos unsuitable for IVF embryo
transfer (ET) could offer a suitable HLA-
match for the regional population from
which the banked lines were derived.
A total of 692 blastocysts obtained from
various abnormal embryos were collected
after obtaining written informed consent
from both gamete donors and the
approval of the hospital ethical committee.
The collected blastocysts were not
suitable for IVF-ET because they were
obtained from poor-quality embryos on
day 3 postfertilization, had an abnormal
number of pronuclei at the zygote stage,
showed abnormalities in the preimplanta-
tion genetic diagnosis (PGD), or were ob-
tained from artificially parthenoactivated
oocytes. A serum-free mechanical deriva-
tion method was adopted to facilitate
the potential clinical application of these
cell lines (see Supplemental Experimental
Procedures available online), and 188
hESC lines were successfully established.
We observed that the quality of the
inner cell mass (ICM) of individual blasto-
cysts correlated with the derivation effi-
ciency. The rate of successful isolation
of hESC lines was significantly higher
when we used blastocysts with high- or
medium-quality ICMs (grade A and B, as
previously described [Gardner et al.,
2000]). In our study, 69 cell lines were
derived from 170 blastocysts with grade
A ICMs (40.6%); 99 cell lines were derived
from 332 blastocysts with grade B ICMs
(29.8%); and 6 cell lines were derived
from 83 blastocysts with grade C ICMsCell Stem Cell 5,(7.2%) (Table 1 and Figure S1). The ICM
grade reflects the size and degree of
compactness of ICM; therefore, high-
grade ICMs may yield more pluripotent
cells and thus favor more efficient deriva-
tion. Another factor affecting the deriva-
tion efficiency is the developmental stage
of the ICM used for derivation (Chen et al.,
2009). Chen et al. reported that the ICM
and trophectoderm cells are committed
to a restricted fate on day 6 postfertiliza-
tion, and therefore, the derivation effi-
ciency obtained with day 6 or older ICMs
is at least 5-fold higher than that obtained
with day 5 ICMs (26%–52% versus 5%)
(Chen et al., 2009). However, we ob-
served that the derivation efficiency for
day 5 blastocysts was comparable to
that for day 6 and day 8 blastocysts (p >
0.05), and the highest derivation-efficiency
value for day 5 blastocysts was 32.0%
(Table 1). These differences may be attrib-
uted to the influence of the different
embryo culture medium on the timing of
fate restriction; alternatively, the relatively
larger number of day 5 blastocysts (50 in
this study compared to 19 blastocysts in
the Chen et al. study) may have decreased
the bias in sample collection.
Interestingly, although the clinical data
from IVF procedures has shown that
poor-quality embryos have a high rate
(64%–86.6%) of aneuploidy (Findikli
et al., 2004; Pellestor, 1995), the rates of
abnormal karyotypes in the hESC lines
derived from ICMs of different grades
were neither high nor significantly
different (Table 1). A similar pattern was
observed with respect to the zygotic
types from which the hESC lines were
derived (Figure S2). In our established cell
lines, 52 lines were isolated from 137 mo-
nopronuclear (1PN) blastocysts; 19 linesNovember 6, 2009 ª2009 Elsevier Inc. 461
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Categories
Number of Blastocyst
Used for Derivation
hESC Lines
Derived
Derivation
Efficiency (%)
Number of hESC Lines
with Abnormal Karyotype
Abnormality
Rate (%)
ICM Grade
A 170 69 40.6a 9 13.0
B 332 99 29.8b 17 17.2
C 83 6 7.2 1 16.7
Othersc 107 14 13.1 8 57.1
Day of Derivation Postfertilization
D5 50 16 32.0 - -
D6 468 138 29.5 - -
D7 120 22 18.3 - -
D8 10 2 20.0 - -
N/D 44 10 22.7 - -
Pronuclear Type
2PN 254 68 25.8 8 10.3
NPN 62 19 30.6 3 15.8
1PN 137 52 38.0 1 1.9
3PN 145 33 22.8 15 42.4d
Othersc 94 16 17.0 8 50.0
Total 692 188 27.2 35 17.6
The derivation efficiency is expressed as the percentage of cell lines obtained from among the total number of blastocysts used for derivation. The
abnormal rate is expressed in terms of the percentage of abnormally karyotypic hESC lines from among the total number of cell lines established.
a p = 4.9 3 108 comparison of the derivation efficiencies for grades A and C; p = 0.015524, comparison of the derivation efficiencies for grades
A and B.
b p = 0.000023, comparison of the derivation efficiencies for grades B and C.
c Others include embryos with undetermined ICM grades and pronuclear types and embryos that were diagnosed with chromosomal abnormalities by
PGD (see Table S1).
d p = 0.000153, comparison of the derivation efficiencies for 2PN and 3PN cells; p = 0.000001, comparison of the derivation efficiencies for 1PN and
3PN cells; p = 0.03037, comparison of the derivation efficiencies for NPN and 3PN cells.were isolated from 62 nonpronuclear
(NPN) blastocysts; and 33 lines were iso-
lated from 145 triple-pronuclear (3PN)
blastocysts (Table 1). One cell line iso-
lated from 1PN zygotes showed karyo-
typic abnormalities, and this finding is
consistent with the reports showing that
more than 70% of 1PN embryos are actu-
ally diploid embryos (Sultan et al., 1995;
Staessen and Van Steirteghem, 1997).
Surprisingly, half (15 out of the 30 karyo-
typed cell lines) of the cell lines from
3PN zygotes showed a normal karyotype,
and this finding is not consistent with the
previously reported finding that 81.9% of
3PN embryos show chromosomal abnor-
malities (Pellestor, 1995). These results
indicate that either ICM development or
hESC derivation selects for normal ploidy.
Considering the findings of a previous
report (Lerou et al., 2008) that showed
that poor-quality embryos generate
euploid hESC lines, we suggest that the
embryos discarded because of various
abnormalities are valuable resources462 Cell Stem Cell 5, November 6, 2009 ª20for hESC derivation, given that these
embryos may be more acceptable on
ethical grounds and yield euploid cell lines
with high efficiency.
To ensure reliable cryopreservation and
to perform the necessary characterization
of the cell lines, we cultured all the lines
continuously for at least 2 months. Immu-
nostaining and reverse transcription poly-
merase chain reaction (PCR) were used
for identifying the expression of hESC-
specific markers on the individual lines,
which also exhibited high telomerase
activity (Figure S3). Most of the cell lines
showed in vitro differentiation into three
germ layers through embryoid-body
differentiation (Figure S3). In vivo differen-
tiation assays have been performed on 26
cell lines to date, and each line was able to
form teratomas with a complex pattern of
differentiation to three germ layers (Fig-
ure S3). The characteristics of each line
are summarized in Table S1 and indicate
that each analyzed cell line exhibits prop-
erties characteristic of hESCs. More infor-09 Elsevier Inc.mation on these characteristics is avail-
able on our stem cell bank website (http://
www.hescbank.cn). To facilitate distinc-
tion of individual cell lines in the cases of
potential cross contamination during
routine culture, we analyzed the DNA-
fingerprinting profile of each cell line and
found that the profiles for each cell line
were distinct (Table S2).
To evaluate the HLA-matching capacity
of this bank with respect to the regional
population, we utilized a relatively low-
resolution, serology-level method to
determine the genotypes at the HLA-A,
HLA-B, and HLA-DRB1 loci in the 188
hESC lines and also determined the ABO
blood groups for each case (Table S3).
A group of 174 cell lines with diploid geno-
types was chosen for HLA-matching esti-
mation. We considered the entire local
population to be prospective patients
who required stem cell therapy and
obtained representative HLA and ABO
blood type data from 5236 unrelated indi-
viduals (2877 men and 2359 women) from
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Brief ReportFigure 1. Human Leukocyte Antigen Analysis of 174 hESC Lines and 5236 Individuals from Hunan
(A) Frequency distribution of the human leukocyte antigen (HLA) gene in 174 hESC lines and 5236 individuals from Hunan. Most of the major high-frequency alleles
showed similar distribution in the 174 hESC lines and the 5236 individuals. Four alleles showed significant difference: #HLA-A*01, p < 0.01; *HLA-B*40(60), HLA-
B*48, and HLA-DRB1*04, p < 0.025.
(B) Cumulative percentages of the presumptive patients (n = 5236) with an HLA-matched donor in the hESC bank (n = 174) at the six mismatch levels: 0-0-0, zero
HLA-A, HLA-B, and HLA-DRB1 mismatch; 1-0-0, zero HLA-B, and HLA-DRB1 mismatch with a single HLA-A mismatch or better; 0-1-0, zero HLA-A and HLA-
DRB1 mismatch with a single HLA-B mismatch or better; 0-0-1, zero HLA-A and -B mismatch with a single HLA-DRB1 mismatch or better; 1-1-0, zero HLA-DRB1
mismatch with a single HLA-A and a single HLA-B mismatch or better; and *-*-0; zero HLA-DRB1 mismatch.
(C) The proportions of the HLA-matching rates of the eight HLA homozygous hESC lines and the other cell lines in the bank.
(D) HLA-matching proportions of the Han group and the minority group.the Hunan branch of the Chinese Marrow
Donor Program (CMDP). Subsequently,
using the 174 lines in our hESC bank as
the presumptive-donor group, we calcu-
lated the matching rate. We first compared
the allele frequencies at the HLA-A,
HLA-B, and HLA-DRB1 loci in the cell lines
and the population. Although there were
differences in the frequencies of the alleles
A*01, B*40(60), B*48, and DRB1*04, the
major high-frequency alleles in our cell
lines and the patients were similar (Fig-
ure 1A and Table S4), indicating that there
is no significant difference between theHLA distributions in IVF patients and the
local population.
To estimate the proportion of the popu-
lation that would benefit from the hESC
bank, we calculated the number of people
who would be able to find at least one
HLA-matched hESC line with a compat-
ible ABO blood type. We repeated the
calculations on a series of cell-line
subsets of increasing size, with the
maximum size being 174 cell lines. The
analysis was repeated for six different
levels of HLA matching. We found that
an increase in the number of hESC linesCell Stem Cell 5,used for matching corresponded to an
increase in the HLA-matching rate. When
all the 174 lines were considered, a fully
matched hESC line (0-0-0) was obtained
for 24.9% of the population; a single
HLA-A mismatch or better (1-0-0) was
obtained for 35.1% of the population; a
single HLA-B mismatch or better (0-1-0)
was obtained for 56.3% of the population;
a single HLA-DRB1 mismatch or better
(0-0-1) was obtained for 49.8% of the
population; single mismatches at 2 loci of
HLA-A and HLA-B or better (1-1-0) were
obtained for 83.4% of the population;November 6, 2009 ª2009 Elsevier Inc. 463
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was obtained for 93.5% of the population
(Figure 1B). These results, obtained from
an established hESC bank and compared
with actual population data, are similar to
the previously obtained theoretical calcu-
lations (Taylor et al., 2005; Nakajima et al.,
2007).
Homozygous cell lines for the common
HLA haplotypes are regarded as a valu-
able resource for stem cell banking (Tay-
lor et al., 2005; Nakajima et al., 2007).
Among the 174 hESC lines, we identified
eight lines that were homozygous at the
three loci; these lines showed only five
HLA haplotypes (Table S5). Remarkably,
these lines contributed to more than
50%–80% of the total matching rates at
the different mismatch levels (Figure 1C).
Among the five HLA haplotypes, three
were common (haplotype frequency >
2%) in the 5236 presumptive patients
(Table S4) and contributed to 90% of
the total matching rate of HLA-homozy-
gous cell lines (Table S6). This finding indi-
cates that the collection of homozygous
hESC lines with common HLA types will
be preferable for clinical hESCs banking.
Because of the low incidence (1.5%) of
HLA-homozygous individuals in the
normal population (Taylor et al., 2005),
researchers have suggested that homo-
zygous embryos should be produced
through parthenogenesis or IVF of
prescreened HLA-homozygous donors
(Nakajima et al., 2007; Revazova et al.,
2008), or by directly deriving pluripotent
cells from prescreened donors by
somatic-cell nuclear transfer (SCNT) or
induced pluripotent stem cell (iPSC) tech-
nology (Taylor et al., 2005; Nakatsuji et al.,
2008). Here, we observed that one of the
two established parthenogenetic ESC
(pESC) lines (chHES-177; Table S1) is
HLA homozygous, which is consistent
with the previous finding that the MHC
loci in some of the pESC lines may be
heterozygous as a result of early recombi-
nation during meiosis (Kim et al., 2007a,
2007b). Further, the other seven HLA-
homozygous cell lines are derived from
various abnormal embryos such as 1PN
(two cell lines), 3PN (one cell line), and
poor-quality 2PN (four cell lines) embryos.
To determine whether these seven homo-
zygous cell lines are derived from sponta-
neous parthenogenesis during IVF, we
performed genome-wide single-nucleo-
tide polymorphism (SNP) analysis with464 Cell Stem Cell 5, November 6, 2009 ª2the Affymetrix Genome-wide SNP array
5.0. The results (Figure S4) indicate that
chHES-32 is a homozygous diploid par-
thenote because of duplication of a single
haploid pronucleus (Lin et al., 2007),
unlike the standard pESC line chHES177,
which was created by prevention of
second-polar-body extrusion, resulting
in partial heterozygosity caused by failure
to segregate the rearranged chromo-
somes at meiosis II. In contrast, the other
six HLA-homozygous cell lines are highly
heterozygous and do not exhibit a peri-
centromeric homozygosity pattern on
the chromosomes, as observed in pESCs
(Kim et al., 2007b). The incidence of HLA-
homozygous cell lines (7 out of 172, 4.1%)
in abnormal embryos is higher than the
incidence of HLA-homozygous individ-
uals in a normal population (57 out of
5236, 1.1% in this study [p = 0.001] and
1.5% in Taylor’s study [p = 0.013]), and
this finding further indicated that the clin-
ically unsuitable embryos are a more
feasible source of HLA-homozygous cell
lines than parthenogenetically activated
human oocytes.
Finally, to determine whether our hESC
bank could benefit the ethnic minorities in
the local population, we calculated the
matched proportions of both the majority
Han group (n = 5132) and the minority
group (n = 104). The matching rates for
the two groups were comparable at
each of the six mismatch grades (Fig-
ure 1D). This result suggests that the
hESC bank can be equally beneficial for
both the Han population and other ethnic
groups in the local population.
Some HLA alleles are associated with
particular diseases (Klein and Sato, 2000),
and different transplantation procedures
require different levels of HLA matching
(Sheldon and Poulton, 2006; Opelz et al.,
1999; Petersdorf et al., 1998); therefore,
the minimum number of cell lines required
in a hESC bank would vary according to
the disease being treated. Nevertheless,
this study provides evidence that a
hESC bank consisting of mainly euploid
cell lines can be established from clinically
rejected embryos, and this cell bank
can serve as a resource for potential
cell-replacement therapy in a regional
population. Our bank can provide a
suitable match (one mismatch only or
better) for 16.96–38.26 million people
of both Han and other ethnic Chinese
groups among the 68 million people009 Elsevier Inc.in the Hunan population. In addition,
this bank can provide new hESC
resources for the entire stem cell research
community.
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